Travere Therapeutics (TVTX) FCF Margin (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly FCF Margin came in at 31.73% in Q1 2026, up 1989.0% YoY from 1.52% in Q1 2025, and down 83.96% on a QoQ basis from 17.25% in Q4 2025.
Travere Therapeutics (TVTX) FCF Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of FCF Margin data on file, last reported at 31.73% in Q1 2026.
- Quarterly FCF Margin rose 1989.0% year-over-year to 31.73% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 56.32% (up 249.0% YoY) and the FY2025 annual result came in at 406.28%, up 50812.0% from the prior year.
- FCF Margin retreated to 31.73% in Q1 2026, from 17.25% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 35.44% in Q3 2025 to a low of 321.42% in Q1 2023.
- A 5-year average of 125.26% and a median of 128.6% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin tumbled 24225 bps — and 2025, when it surged 23576 bps.
- Tracing TVTX's FCF Margin over 5 years: stood at 186.34% in 2022, then slumped by 38 bps to 257.07% in 2023, then soared by 81 bps to 48.25% in 2024, then soared by 64 bps to 17.25% in 2025, then slumped by 84 bps to 31.73% in 2026.
- The last three FCF Margin figures came in at 31.73% (Q1 2026), 17.25% (Q4 2025), and 35.44% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 34.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.24% |
| Mar 31, 2026 | -31.73% |
| Dec 31, 2025 | -17.25% |
| Sep 30, 2025 | 35.44% |
| Jun 30, 2025 | 4.35% |
| Mar 31, 2025 | -51.62% |
| Dec 31, 2024 | -48.25% |
| Sep 30, 2024 | -67.01% |
| Jun 30, 2024 | -74.71% |
| Mar 31, 2024 | -287.38% |
| Dec 31, 2023 | -257.07% |
| Sep 30, 2023 | -159.44% |
| Jun 30, 2023 | -160.79% |
| Mar 31, 2023 | -321.42% |
| Dec 31, 2022 | -186.34% |
| Sep 30, 2022 | -140.83% |
| Jun 30, 2022 | -128.60% |
| Mar 31, 2022 | -236.85% |
| Dec 31, 2021 | 55.91% |
| Sep 30, 2021 | 46.49% |